Royalty Revenue Monetization - Narrative (Details) - USD ($) $ in Thousands		1 Months Ended	6 Months Ended
	Mar. 02, 2026	Mar. 31, 2026	Jun. 30, 2026	Jun. 30, 2025
Deferred Revenue Arrangement [Line Items]
Proceeds from sale of future royalties	$ 250,000	$ 250,000	$ 250,000	$ 0
Issuance costs	$ 5,563		$ 5,563
Jazz And BeOne \| License And Collaboration Agreement \| Collaborative Arrangement
Deferred Revenue Arrangement [Line Items]
Royalty percentage retained	70.00%
Zymeworks Royalty Limited Partnership
Deferred Revenue Arrangement [Line Items]
Future royalty percentage sold	30.00%
Future royalty percentage not to exceed threshold percentage of loan payable	120.00%
Zymeworks Royalty Limited Partnership \| Jazz And BeOne \| License And Collaboration Agreement \| Collaborative Arrangement
Deferred Revenue Arrangement [Line Items]
Future royalty percentage sold	30.00%
Royalty Pharma \| Non-Recourse Secured Term Loan \| Secured Debt \| Zymeworks Royalty Limited Partnership
Deferred Revenue Arrangement [Line Items]
Face amount	$ 250,000
Interest rate			10.70%
Royalty Pharma \| Non-Recourse Secured Term Loan \| Secured Debt \| Zymeworks Royalty Limited Partnership \| Amount Due If Paid At Maturity
Deferred Revenue Arrangement [Line Items]
Long-term debt	481,300
Royalty Pharma \| Non-Recourse Secured Term Loan \| Secured Debt \| Zymeworks Royalty Limited Partnership \| Amount Due If Paid On Or Before December 31, 2033
Deferred Revenue Arrangement [Line Items]
Long-term debt	$ 412,500